Skip to main content

Vaccine Development: From Preclinical Studies to Phase 1/2 Clinical Trials

  • Protocol
  • First Online:
Malaria Control and Elimination

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2013))

Abstract

Vaccines are biological pharmaceutical products prescribed as prevention of a hypothetical infection. Development of a new vaccine is the result of a long process involving several stages. During all developmental phases, priority is the safety of the new product, which is often used in young infants. The initial research phase lasts 1–5 years and is followed by a clinical and pharmaceutical development phase (preclinical and clinical phases), which can last from 15 to 20 years on average before licensure is obtained. There are, however, exceptions, like the malaria vaccine for which research has been going on for more than 30 years and at least 30 candidate vaccines have been assessed. This chapter summarizes the different phases of vaccine candidate development from preclinical studies to phase 2 vaccine trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lebron JA, Wolf JJ, Kaplanski CV et al (2005) Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines 46:855–866

    Article  Google Scholar 

  2. World Health Organization (2003) Guidelines on nonclinical evaluation of vaccines. World Health Organization, Geneva

    Google Scholar 

  3. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (1999) Specifications: test procedures and acceptance criteria for biotechnological/biological products, Q6B

    Google Scholar 

  4. Prescott MJ, Lidster K (2017) Improving quality of science through better animal welfare: the NC3Rs strategy. Lab Anim 46:152–156

    Article  Google Scholar 

  5. Forster R (2012) Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods 66:1–7

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Odile Launay .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Artaud, C., Kara, L., Launay, O. (2019). Vaccine Development: From Preclinical Studies to Phase 1/2 Clinical Trials. In: Ariey, F., Gay, F., Ménard, R. (eds) Malaria Control and Elimination. Methods in Molecular Biology, vol 2013. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9550-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9550-9_12

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9549-3

  • Online ISBN: 978-1-4939-9550-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics